Schroder Investment Management Group
ARCT icon

Schroder Investment Management Group’s Arcturus Therapeutics ARCT Stock Holding History

Schroder Investment Management Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,150
Closed -$294K – 1404
2021
Q3 		$294K Buy
+6,150
New +$276K ﹤0.01% 1283
2021
Q2 		– Sell
-32,059
Closed -$1.32M – 1516
2021
Q1 		$1.32M Sell
32,059
-55,466
-63% -$3.31M ﹤0.01% 1093
2020
Q4 		$3.8M Buy
87,525
+27,097
+45% +$1.84M 0.01% 863
2020
Q3 		$2.59M Buy
+60,428
New +$3M ﹤0.01% 851

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group's ARCT Position: Q4 2021 in Review

Schroder Investment Management Group sold out of Arcturus Therapeutics (ARCT) in Q4 2021, closing a stake of 6,150 shares — an estimated $294K sold.

Schroder Investment Management Group first reported a position in ARCT in Q3 2020 and held it in 4 quarters. The position peaked at $3.8M in Q4 2020. 139 funds tracked by Wall St. Rank hold ARCT as of Q4 2021.

  • Schroder Investment Management Group reported no remaining Arcturus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Schroder Investment Management Group sold 6,150 Arcturus Therapeutics shares in Q4 2021, an estimated $294K.
  • Schroder Investment Management Group first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 4 quarters.
  • Schroder Investment Management Group's Arcturus Therapeutics position peaked at $3.8M in Q4 2020.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2021.

Based on Schroder Investment Management Group's 13F filing for Q4 2021, filed 14 Feb 2022.